UK MHRA sets path for puberty blocker trial to continue

The controversial trial of puberty blockers was paused in February due to concerns about the well-being of participants. The controversial trial was paused in February due to concerns about the well-being of participants. The controversial trial has led to protests and counter protests in the UK. Credit: Dmitry Demidovich / Shutterstock.com The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared an investigator-led trial investigating puberty blockers in children and young people to continue. The Phase III PATHWAYS trial (ISRCTN12491684), run by King’s College London (KCL), was paused in February 2026 after concerns were raised about the well-being of the…

Source: Clinical Trials Arena